← Leaderboards
Sheung Chee Thomas Ng
Massachusetts General Hospital
$800,006
Attributed
$1,142,059
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $892.2K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$1,142,059 · 2
By mechanism
R01$684,107 · 1
R21$457,952 · 1
Top collaborators
- David T. Miyamoto1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Filip K Swirski$20,484,870
- Alexei A Bogdanov$13,760,247
- David T Scadden$62,181,067
- Hamid Sabet$6,663,195
- Ralph Weissleder$110,468,710
Others in their field
Other Rising Stars on “Staging”
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Michael Hogarth · University Of California, San Diego$14,390,863
- Cathie Snyder · Rho Federal Systems Division, Inc.$13,500,724
- Heinz Ernst Moser · University Of Texas Med Br Galveston$12,973,432
- Daniel Hunter Reirden · Westat, Inc.$11,343,255
- Michael George Natchus · Emory University$10,548,554
Research focus
StagingMalignant NeoplasmsPositron-Emission TomographyTechnologyBenchmarkingFda ApprovedMolecular ImagingPathway InteractionsTumorFolh1 GeneImageNon-Invasive ImagingBioreactorsImaging AgentImaging CapabilitiesHospitalsHalf-LifeImaging FacilitiesAdoptionEquityComplexDrug KineticsBindingCovid-19 Pandemic
Grant awards (3)
Integration of circulating tumor cell and nuclear imaging biomarkers to assess LuPSMA response and resistance in advanced prostate cancer patients$684,107
R01 · FY2025 · CA · contact PI
Optimized and accessible immuno-PET using lipid nanoparticle-mediated in vivo bioreactor$208,091
R21 · FY2025 · EB · contact PI
Optimized and accessible immuno-PET using lipid nanoparticle-mediated in vivo bioreactor$249,861
R21 · FY2024 · EB · contact PI